In a groundbreaking development for the treatment of muscular dystrophies, IPS HEART received Orphan Drug Designation (ODD) from the U.S. FDA on January 13th, 2025, for its innovative stem cell therapy, GIVI-MPCs. GIVI-MPCs are mesenchymal progenitor cells derived from induced pluripotent stem cells (iPSCs) that have the potential to treat Becker Muscular Dystrophy (BMD). This milestone recognizes the therapy’s unprecedented ability to generate new skeletal muscle containing full-length dystrophin—a crucial protein missing or defective in individuals with BMD. [Read more…]
CHU Toulouse receives CTA Approval to initiate ALLOFIST, a Phase 1/2 Trial based on Cell-Easy’s proprietary adipose-derived MSC in Patients suffering from Crohn Disease.
Toulouse, France, January 16, 2025 – The long-term partnership between Cell-Easy and Toulouse University Hospital (CHU Toulouse) continues to bear fruits, bringing innovative MSC-based therapies to local patient cohorts. This time, it’s in the field of Crohn’s disease that the pair is experimenting with the allogeneic cell therapy approach. By tackling all CMC, regulatory and medico-economic concerns, the Cell-Easy CDMO has succeeded in developing a cell therapy drug from scratch in just 2 years. The principal investigator Dr Etienne Buscail, a colo-rectal surgeon and proctologist at Toulouse University Hospital, recently submitted a request for authorization of CTA to the European Agency EMA, which was rapidly accepted. An initial cohort of patients suffering from Crohn’s disease will be able to benefit from this experimental innovant treatment starting in 2025 Q1. [Read more…]
China’s NMPA Approves Country’s First MSC-Based Cell Therapy, Ruibosheng
On January 2, 2025, China’s National Medical Products Administration (NMPA) granted conditional approval to Platinum Life Excellence Biotech Co. Ltd.’s amimestrocel injection (hUC-MSC PLEB-001), marking a significant milestone in the country’s medical and biotechnological advancements. The product is being marketing under the brand name Ruibosheng. This approval designates it as China’s first human umbilical cord-derived mesenchymal stem cell (hUC-MSC) therapy, offering a promising treatment option for steroid-refractory acute graft-versus-host disease (GVHD), a serious and often fatal complication following stem cell transplants. [Read more…]
7 Tactical Ways to Assess Which Stem Cell Procedures Might Work
Stem cell research used to be controversial specifically because of the attention given to embryonic stem cells, which are derived from human embryos. Thankfully, very little research is done on embryonic stem cells anymore, because there are now better, non-controversial alternatives available for research and clinical use. These alternatives include induced pluripotent stem cells (derived from mature human cells) and adult stem cells, which can be sourced from the blood, bone marrow, and fat tissue, for example. [Read more…]
Updates on Stem Cells for Cystic Fibrosis Treatment
In 1938, American doctor Dorothy Anderson noted a condition in which individuals suffered damage to the pancreas, calling it cystic fibrosis. Other physicians of her time and even earlier noted symptoms such as salty skin and thickened mucus, making it hard to breathe and function normally. While in recent decades, scientists have gained a much better understanding of what cystic fibrosis does to the body, they haven’t had nearly as much luck in finding an effective course of cystic fibrosis treatment. Luckily, that may soon change. [Read more…]
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 200
- Next Page »